5-Bromopyridazin-3-amine

Catalog No. :
ACXAML436
CAS No. :
1187237-00-8
Molecular Formula :
C4H4BrN3
Molecular Weight :
174.00

IUPAC Name:5-bromopyridazin-3-amine

5-Bromopyridazin-3-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$153.00Login to see priceIn stockInquiry
100mg98%$243.00Login to see priceIn stockInquiry
250mg98%$393.00Login to see priceIn stockInquiry
1g98%$1039.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Bromopyridazin-3-amine
IUPAC Name5-bromopyridazin-3-amine
MDL No.MFCD18382564
Molecular FormulaC4H4BrN3
Molecular Weight174.00
SMILESNC1=NN=CC(Br)=C1
InChI KeyVIZZTROFAJLFML-UHFFFAOYSA-N
SynonymDTXSID10735912 | 4,7-Bis(5-bromo-4-hexylthiophene-2-yl)benzo[c][1,2,5]thiadiazole | SY324186 | AS-82305 | 3-amino-5-bromopyridazine; | 5-Bromopyridazin-3-amine | P21037 | AMY25224 | 1187237-00-8 | AKOS016013025 | 3-amino-5-bromopyridazine | EN300-223485 |
CAS No.1187237-00-8
PubChem CID66864135

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACXAML436 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKRDF861 route compound structure diagram
    ACKRDF8611196155-35-7 In Stock
  2. Plus
  3. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6 In Stock
  4. Then
  5. ACXAML436 route product structure diagram
    ACXAML4361187237-00-8 In Stock
Inquiry

2. ACXAML436 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACUGAQ384 route compound structure diagram
    ACUGAQ3841196155-33-5 In Stock
  2. Plus
  3. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6 In Stock
  4. Then
  5. ACXAML436 route product structure diagram
    ACXAML4361187237-00-8 In Stock
Inquiry

Comments (0)